Milestone Pharmaceuticals Files 8-K
Ticker: MIST · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1408443
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Milestone Pharma filed an 8-K, likely with financial updates. Keep an eye out.
AI Summary
On March 28, 2024, Milestone Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that Milestone Pharmaceuticals Inc. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural document (8-K) without immediate negative or positive financial implications detailed in the excerpt.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- March 28, 2024 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Milestone Pharmaceuticals Inc. in this 8-K filing?
The provided excerpt does not specify the details of the "Other Events" beyond listing it as an item information category.
What financial statements or exhibits are included with this 8-K filing?
The excerpt lists "Financial Statements and Exhibits" as an item information category but does not detail the specific contents.
What is the principal executive office address for Milestone Pharmaceuticals Inc.?
The principal executive office is located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.
What is the telephone number for Milestone Pharmaceuticals Inc.?
The telephone number is (514) 336-0444.
What is the SIC code for Milestone Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-28 07:07:11
Filing Documents
- tm2410060d1_8k.htm (8-K) — 23KB
- tm2410060d1_ex99-1.htm (EX-99.1) — 15KB
- tm2410060d1_ex99-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-24-040008.txt ( ) — 229KB
- mist-20240328.xsd (EX-101.SCH) — 3KB
- mist-20240328_lab.xml (EX-101.LAB) — 33KB
- mist-20240328_pre.xml (EX-101.PRE) — 22KB
- tm2410060d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On March 28, 2024, Milestone Pharmaceuticals Inc. issued a press release announcing the resubmission of its New Drug Application to the U.S. Food and Drug Administration for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia . A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-Kand is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release, dated March 28, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. Date: March 28, 2024 By: /s/ Amit Hasija Amit Hasija Chief Financial Officer Principal Financial Officer